BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 24, Issue 15
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (18598)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-2) series.
Item 
Count 
PDF1544
WORD299
HTML10269
Figures (1-5)547
Tables (1-2)896
 Sum=13555
Featured Article
The chart showing Browse series, Download series.
Item 
Count 
Browse945
Download908
 Sum=1853
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse1366
Download1825
 Sum=3191
Apr 21, 2018 (publication date) through Oct 22, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
Copyright ©The Author(s) 2018.
World J Gastroenterol. Apr 21, 2018; 24(15): 1601-1615
Published online Apr 21, 2018. doi: 10.3748/wjg.v24.i15.1601
Table 1 List of pathways involved in nonalcoholic fatty liver disease selected from significant Q-values that dependent on both genes and metabolites analyzed jointly
Pathway nameQ-joint
Solute carriers -mediated transmembrane transport1.23E-12
Transmembrane transport of small molecules9.66E-12
Transport of glucose and other sugars bile salts and organic acids metal ions and amine compounds8.40E-10
Leukotriene biosynthesis8.71E-10
Transport of glucose and other sugars bile salts and organic acids metal ions and amine compounds1.91E-09
Transport of inorganic cations-anions and amino acids-oligopeptides4.27E-09
Amino acid and oligopeptide SLC transporters1.10E-08
Transport of inorganic cations/anions and amino acids/oligopeptides2.40E-08
tRNA Aminoacylation3.03E-08
Gamma-glutamyl cycle3.61E-08
tRNA charging5.96E-08
mRNA protein and metabolite induction pathway by cyclosporine A8.47E-08
Class I MHC mediated antigen processing & presentation1.73E-07
Na+/Cl- dependent neurotransmitter transporters3.10E-07
Amino acid transport across the plasma membrane3.72E-07
S-methyl-5-thio-alpha;-D-ribose 1-phosphate degradation6.17E-07
Amine compound solute carrier transporters6.17E-07
Protein digestion and absorption - homo sapiens (human)2.13E-06
Amino acid interconversion2.21E-06
Biochemical pathways part I2.34E-06
Amino acid metabolism3.96E-06
Aminoacyl-tRNA biosynthesis - homo sapiens (human)6.88E-06
Metabolism of amino acids and derivatives8.72E-06
Mineral absorption - homo sapiens (human)1.47E-05
Cytosolic tRNA aminoacylation2.86E-05
Mitochondrial tRNA aminoacylation2.86E-05
tRNA Aminoacylation2.86E-05
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism0.000159
Gene expression0.000181
Tryptophan catabolism0.000275
Phase II conjugation0.000426
Phenylalanine and tyrosine catabolism0.003
Glutamine and glutamate metabolism - homo sapiens (human)0.00376
Glutaminolysis and cancer0.00493
Glycine metabolism0.0052
Glutamate glutamine metabolism0.00665
Recycling of bile acids and salts0.00669
Glycine serine alanine and threonine metabolism0.0101
Branched-chain amino acid catabolism0.0103
OMICs-integrative analysis was performed using the IMPaLA (integrated molecular pathway level analysis, http://impala.molgen.mpg.de)[67] platform. A joined adjusted P-value (Q-value) was calculated to control for multiple testing by false discovery rate.
Full Size Table
Table 2 List of pathways involved in nonalcoholic fatty liver disease selected from significant Q-values independently on whether they represent the effect of gene/s or metabolite/s only
Pathway namePathway sourceQ-joint
AdipogenesisWikipathways2.00E-17
Non-alcoholic fatty liver disease (NAFLD) - homo sapiens (human)KEGG2.33E-17
MetabolismReactome3.72E-17
AGE-RAGE pathwayWikipathways4.22E-17
Vitamin B12 MetabolismWikipathways5.24E-17
Hepatitis B - homo sapiens (human)KEGG1.79E-16
Folate metabolismWikipathways1.29E-15
Selenium micronutrient networkWikipathways3.87E-15
TNF signaling pathway - homo sapiens (human)KEGG5.77E-15
JAK-STAT-coreSignalink1.99E-14
Adipocytokine signaling pathway - homo sapiens (human)KEGG7.07E-14
Nuclear receptors meta-pathwayWikipathways1.26E-13
IL1 and megakaryocytes in obesityWikipathways2.73E-13
AGE-RAGE signaling pathway in diabetic complications - homo sapiens (human)KEGG3.79E-13
Spinal cord injuryWikipathways5.44E-13
Malaria - homo sapiens (human)KEGG7.09E-13
Metabolism of lipids and lipoproteinsReactome7.09E-13
SLC-mediated transmembrane transportReactome1.23E-12
Pathways in cancer - homo sapiens (human)KEGG1.41E-12
Inflammatory bowel disease (IBD) - homo sapiens (human)KEGG2.25E-12
Lung fibrosisWikipathways2.63E-12
Integrated pancreatic cancer pathwayWikipathways3.10E-12
PI3K-Akt signaling pathway - homo sapiens (human)KEGG3.28E-12
Chagas disease (American trypanosomiasis) - homo sapiens (human)KEGG4.67E-12
HIF-1 signaling pathway - homo sapiens (human)KEGG4.67E-12
AMPK signaling pathway - homo sapiens (human)KEGG9.56E-12
Transmembrane transport of small moleculesReactome9.66E-12
Central carbon metabolism in cancer - homo sapiens (human)KEGG1.41E-11
Jak-STAT signaling pathway - homo sapiens (human)KEGG5.75E-11
DNA damage response (only ATM dependent)Wikipathways7.27E-11
Cytokine-cytokine receptor interaction - homo sapiens (human)KEGG1.01E-10
Longevity regulating pathway - homo sapiens (human)KEGG1.02E-10
Toll-like receptor signaling pathwayWikipathways2.12E-10
Toll-like receptor signaling pathway - homo sapiens (human)KEGG3.94E-10
Toxoplasmosis - homo sapiens (human)KEGG4.73E-10
ABC transporters - homo sapiens (human)KEGG5.94E-10
Transport of glucose and other sugars bile salts and organic acids metal ions and amine compoundsWikipathways8.40E-10
Leukotriene biosynthesisHumanCyc8.71E-10
Insulin resistance - homo sapiens (human)KEGG1.14E-09
Transport of glucose and other sugars bile salts and organic acids metal ions and amine compoundsReactome1.91E-09
Sudden infant death syndrome (SIDS) susceptibility pathwaysWikipathways2.12E-09
Cytokines and inflammatory responseWikipathways2.17E-09
AP-1 transcription factor networkPID2.22E-09
FoxO signaling pathway - homo sapiens (human)KEGG3.05E-09
Leptin signaling pathwayWikipathways3.57E-09
Transport of inorganic cations-anions and amino acids-oligopeptidesWikipathways4.27E-09
Oncostatin M signaling pathwayWikipathways5.72E-09
Focal adhesion-PI3K-Akt-mTOR-signaling pathwayWikipathways6.53E-09
Amino acid and oligopeptide SLC transportersReactome1.10E-08
ApoptosisWikipathways1.41E-08
Apoptotic signaling pathwayWikipathways1.41E-08
Photodynamic therapy-induced NF-kB survival signalingWikipathways1.84E-08
JAK STAT molecularvariation 1INOH2.04E-08
MAPK signaling pathwayWikipathways2.04E-08
Aryl hydrocarbon receptorWikipathways2.35E-08
Transport of inorganic cations/anions and amino acids/oligopeptidesReactome2.40E-08
tRNA aminoacylationWikipathways3.03E-08
gamma-glutamyl cycleHumanCyc3.61E-08
Glucose homeostasisWikipathways4.08E-08
Validated transcriptional targets of AP1 family members Fra1 and Fra2PID4.13E-08
Hepatitis C and hepatocellular carcinomaWikipathways4.26E-08
Calcineurin-regulated NFAT-dependent transcription in lymphocytesPID4.29E-08
Prostate cancer - homo sapiens (human)KEGG4.29E-08
Tuberculosis - homo sapiens (human)KEGG4.45E-08
Apoptosis - homo sapiens (human)KEGG4.54E-08
tRNA chargingHumanCyc5.96E-08
Transcription factor regulation in adipogenesisWikipathways6.27E-08
Sterol regulatory element-binding proteins (SREBP) signallingWikipathways6.27E-08
Integrated lung cancer pathwayWikipathways6.43E-08
TNF related weak inducer of apoptosis (TWEAK) signaling pathwayWikipathways8.14E-08
mRNA protein and metabolite inducation pathway by cyclosporin AWikipathways8.47E-08
PPAR signaling pathwayWikipathways9.54E-08
Immune systemReactome9.57E-08
Regulation of lipid metabolism by peroxisome proliferator-activated receptor alpha (PPARalpha)Wikipathways1.13E-07
AMP-activated protein kinase (AMPK) signalingWikipathways1.34E-07
Photodynamic therapy-induced NFE2L2 (NRF2) survival signalingWikipathways1.52E-07
Leptin insulin overlapWikipathways1.65E-07
Class I MHC mediated antigen processing and presentationWikipathways1.73E-07
Caspase cascade in apoptosisPID1.99E-07
Overview of nanoparticle effectsWikipathways2.17E-07
Alpha6Beta4IntegrinNetPath2.29E-07
VEGFA-VEGFR2 signaling pathwayWikipathways2.30E-07
HIV-1 Nef: Negative effector of Fas and TNF-alphaPID2.65E-07
Innate immune systemReactome2.69E-07
Na+/Cl- dependent neurotransmitter transportersReactome3.10E-07
Colorectal cancer - homo sapiens (human)KEGG3.42E-07
Regulation of toll-like receptor signaling pathwayWikipathways3.64E-07
stress induction of hsp regulationBioCarta3.64E-07
Amino acid transport across the plasma membraneReactome3.72E-07
Programmed cell deathReactome3.85E-07
Apoptosis modulation and signalingWikipathways4.42E-07
SREBF and miR33 in cholesterol and lipid homeostasisWikipathways4.84E-07
JAK STAT pathway and regulationINOH5.42E-07
OMICs-integrative analysis was performed using the IMPaLA (Integrated Molecular Pathway Level Analysis, http://impala.molgen.mpg.de)[67] platform. A joined adjusted P-value (Q-value) was calculated to control for multiple testing by false discovery rate.
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345